| Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative KM Andersen, BA Bates, ES Rashidi, AL Olex, RB Mannon, RC Patel, ... The Lancet Rheumatology 4 (1), e33-e41, 2022 | 121 | 2022 |
| Fentanyl and fentanyl analogs in the illicit stimulant supply: results from US drug seizure data, 2011–2016 JN Park, E Rashidi, K Foti, M Zoorob, S Sherman, GC Alexander Drug and alcohol dependence 218, 108416, 2021 | 93 | 2021 |
| Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using … CA Salinas, A Louder, J Polinski, TC Zhang, H Bower, S Phillips, Y Song, ... Rheumatology and Therapy 10 (1), 201-223, 2023 | 59 | 2023 |
| Use of hydroxychloroquine, remdesivir, and dexamethasone among adults hospitalized with COVID-19 in the United States: a retrospective cohort study HB Mehta, H An, KM Andersen, O Mansour, V Madhira, ES Rashidi, ... Annals of internal medicine 174 (10), 1395-1403, 2021 | 31 | 2021 |
| Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin R Qureshi, E Mayo-Wilson, T Rittiphairoj, M McAdams-DeMarco, ... Journal of clinical epidemiology 143, 212-223, 2022 | 19 | 2022 |
| Characteristics of copayment offsets for prescription drugs in the United States AP Sen, SY Kang, E Rashidi, D Ganguli, G Anderson, GC Alexander JAMA internal medicine 181 (6), 758-764, 2021 | 13 | 2021 |
| Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms R Qureshi, E Mayo-Wilson, T Rittiphairoj, M McAdams-DeMarco, ... Journal of clinical epidemiology 143, 224-241, 2022 | 8 | 2022 |
| National COVID Cohort Collaborative Consortium: Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the … KM Andersen, BA Bates, ES Rashidi, AL Olex, RB Mannon, RC Patel, ... Lancet Rheumatol 4 (1), e33, 2022 | 6 | 2022 |
| The Price Paradox of Biosimilar-Like Long-Acting Insulin. MC Mouslim, ES Rashidi, JF Levy, MP Socal, AJ Trujillo American Journal of Managed Care 28 (11), 2022 | 1 | 2022 |
| Performance of Elixhauser and Charlson Comorbidity Indices to predict mortality among adults hospitalized with COVID-19 in the United States KM Andersen, E Rashidi, BT Garibaldi, GC Alexander, JB Segal, ... Pharmacoepidemiology and Drug Safety, 402-402, 2021 | 1 | 2021 |
| Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using … CASAL Jennifer, PTCZH Bower, SPYSE Rashidi, RBHCC Nicole, ... | | 2022 |
| Effect of biosimilar basaglar entry in the long-acting insulin market E Rashidi PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 30, 407-407, 2021 | | 2021 |
| Characteristics of Copayment Offsets for Prescription Drugs in the United States (Mar, 10.1001/jamainternmed. 2021.0733, 2021) AP Sen, SY Kang, E Rashidi, D Ganguli, G Anderson, GC Alexander JAMA INTERNAL MEDICINE 181 (6), 883-883, 2021 | | 2021 |
| Erratum: Characteristics of copayment offsets for prescription drugs in the United States (JAMA Intern Med (2021 AP Sen, SY Kang, E Rashidi, D Ganguli, G Anderson, GC Alexander JAMA internal medicine 181 (6), 883, 2021 | | 2021 |
| Use of hydroxychloroquine, remdesivir, and dexamethasone among adults hospitalized with COVID-19 in the United States: Results from the National COVID Cohort Collaborative (N3C) HB Mehta, HJ An, KM Andersen, O Mansour, V Madhira, ES Rashidi, ... Pharmacoepidemiology and Drug Safety, 27-27, 2021 | | 2021 |
| Utilizing the National COVID Cohort Collaborative (N3C) to evaluate risk of serious outcomes with COVID-19 among chronically immunosuppressed persons KM Andersen, ES Rashidi, HJ An, HB Mehta, DK Ng, BT Garibaldi, ... Pharmacoepidemiology and Drug Safety, 24-24, 2021 | | 2021 |
G. Caleb AlexanderJohns Hopkins Center for Drug Safety and EffectivenessVerified email at jhsph.edu
